Telehealth companies have begun prescribing GLP-1 obesity medications for indications beyond weight loss, and addiction treatment is the next commercial target. The STAT report noted that some telehealth brands are already marketing these drugs directly to consumers, while biotech firms such as Eli Lilly and Altimmune are conducting trials to examine whether the agents curb alcohol cravings. Investigators reported a broader context: the Food and Drug Administration has not approved a new medication for alcohol use disorder in two decades, which helps explain clinical interest and commercial momentum. The STAT piece did not include detailed efficacy data from those trials or regulatory timelines; it simply summarized current activity and market signals.
Federal officials executed searches and delivered warning letters to nearly 100 providers in New York, asserting that Medicaid billing by some Social Adult Day Care programs greatly exceeded peers. Centers for Medicare and Medicaid Services Administrator Mehmet Oz joined law enforcement in actions that led to arrests of two providers alleged to have defrauded Medicaid of more than $500,000, according to the report. The program provides socialization, personal care, and meals for adults with physical and cognitive disabilities; investigators alleged systemic overbilling in some operations. The STAT article cited that the federal crackdown is part of a broader enforcement push, and noted political debate over whether the effort disproportionately targets certain states. The source did not supply judicial outcomes beyond the arrests or provide detailed provider-level audit methods.
A trial published in Clinical Gastroenterology and Hepatology tested a home-based exercise and diet program for patients awaiting liver transplant. The research team from Northwestern Medicine and the University of Pittsburgh enrolled patients who met with a physical therapist and a dietitian to design individualized plans aiming for 150 minutes of weekly activity. STAT summarized the trial’s outcomes: about two-thirds of patients improved on a frailty score that measures grip strength, chair stands, and balance. Patients who attended at least three follow-up visits improved by at least 0.4 points on the 4.5-point frailty scale, and the authors reported that that magnitude of improvement corresponded with roughly a 50% lower risk of dying while on the waitlist. The STAT summary reported the investigators’ stated intention to confirm findings in a larger trial; the article did not present additional trial methodology, subgroup analyses, or p-values.
Workers’ costs for family coverage rose sharply in 2026. KFF’s 2026 Employer Health Benefits Survey found that average worker premium contributions for a family plan increased 9% from the prior measurement period, reaching $7,471. The STAT authors reported that small-business employees experienced even larger premium jumps. The survey attributed the premium increases chiefly to rising overall health care costs. Employers, the authors noted, have absorbed much of those increasing costs so far; however, STAT cited signs that small employers are retreating from offering coverage, a trend that could reduce employer-sponsored access if it continues.
Employers are not insulated from continued cost pressures. The STAT report relayed experts’ concern that employers may be approaching a breaking point, and that premium increases could intensify in the year ahead. The article did not include detailed plan-level actuarial data, nor did it provide the KFF survey’s complete methodological appendix within the text; readers were directed to the KFF publication for full survey details.
The Commonwealth Fund Biennial Health Insurance Survey documented an increase in the uninsured rate among working-age U.S. adults from 8.9% in 2024 to 11.2% in 2026. STAT summarized the survey team’s attribution of that rise to two policy changes: the expiration of Affordable Care Act marketplace premium tax credits and rollback of pandemic-era protections that had kept some people enrolled in Medicaid. STAT reported a striking access consequence: half of uninsured respondents said they skipped needed medical care because of cost concerns.
STAT also flagged an impending policy environment that may further constrict coverage: the article stated that projected 2027 changes — specifically Medicaid cuts and Affordable Care Act marketplace restrictions — are expected to make it harder for Americans to obtain health insurance. The source did not enumerate those 2027 policy changes in detail; it referenced the Commonwealth Fund report for the survey findings and broader policy context.
The STAT package bundled additional items touching on leadership turnover at a diabetes association, a Supreme Court action related to trans health care in prisons, a halted controversial vaccine trial in African newborns, and work by states to expand hospital financial aid programs. These links were presented as curated reading rather than primary data.
Limitations and outstanding questions
The STAT article relied on two major survey sources for headline figures: KFF’s Employer Health Benefits Survey and the Commonwealth Fund’s Biennial Health Insurance Survey. STAT summarized headline statistics and policy implications but did not reproduce full survey methodologies, confidence intervals, or subgroup breakdowns. The article did not provide trial-level data or regulatory timelines for the GLP-1 programs described, nor did it report detailed outcomes beyond the frailty-change and survival association from the liver transplant prehabilitation study. Key unanswered questions in the reporting include the durability of employer-sponsored coverage if premiums continue to rise, the pace at which policy changes in 2027 will affect enrollment and access, and whether off-label GLP-1 use for addiction will yield clinically meaningful benefits when formal trial results emerge.